Similar articles

• Clinical decisions. Management of incidental hepatitis C virus infection.

  Afdhal NH, Lok AS, Di Bisceglie AM. Afdhal NH, et al. N Engl J Med. 2009 Apr 30;360(18):1902-6. doi: 10.1056/NEJMclde0900131. N Engl J Med. 2009. PMID: 19403909 No abstract available.
• Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.

  Yu ML, Dai CY, Huang JF, Chuang WL. Yu ML, et al. Hepatology. 2008 Sep;48(3):1019-20; author reply 1020-1. doi: 10.1002/hep.22434. Hepatology. 2008. PMID: 18756469 No abstract available.
• [Guidelines for treatment of hepatitis C].

  Iino S. Iino S. Nihon Rinsho. 2004 Jul;62 Suppl 7(Pt 1):342-6. Nihon Rinsho. 2004. PMID: 15359818 Review. Japanese. No abstract available.
• [Genotype 1 superresponder treat for only 24 weeks].

  [No authors listed] [No authors listed] MMW Fortschr Med. 2005 Dec 15;147(51-52):69. MMW Fortschr Med. 2005. PMID: 16402717 German. No abstract available.
• Therapy of hepatitis C: from empiricism to eradication.

  Pawlotsky JM. Pawlotsky JM. Hepatology. 2006 Feb;43(2 Suppl 1):S207-20. doi: 10.1002/hep.21064. Hepatology. 2006. PMID: 16447262 Review.